Expanded relationship will build upon established processes initiated in 2019 to meet ASC Therapeutics clinical program WILMINGTON, Mass.–(BUSINESS WIRE)–Charles River Laboratories International, Inc. (NYSE: CRL)

Public, private and non-profit organizations have joined forces to create a standardized approach that will reduce up-front costs and lower barriers to developing novel gene

First known bovine model used to demonstrate safety and efficacy in gene replacement therapy MSUD is a severe genetic disease with liver transplantation or dietary

Podium presentation highlights significant transduction and transgene expression in pharmacokinetic studies in mice, non-human primates and a humanized liver model Poster presentation focuses on pharmacology,

The U.S. Food and Drug Administration (FDA) has given fast track designation to ASC618, an investigational one-time gene therapy for hemophilia A in the pipeline of ASC Therapeutics. Fast

We are very pleased with the FDA’s and EMA’s regulatory decisions regarding ASC618. This brings us one step closer for providing a truly novel therapeutic approach for hemophilia A, providing potentially a functional cure for patients who currently require life-long care.

Experienced in manufacturing of next-generation hemophilia gene therapies at uniQure Experienced in transformational cell culture manufacturing Consolidates global leadership team of gene and cell therapy

Second-generation gene therapies can increase protein synthesis and secretion Minimizing cellular stress can increase durability of liver-targeted gene therapies A peer-reviewed, open-access, comprehensive seminal review

UMass Medical School researchers Guangping Gao, PhD, and Dan Wang, PhD, are working with ASC Therapeutics, a privately held biopharmaceutical company developing in-vivo gene replacement,

MILPITAS, Calif.–(BUSINESS WIRE)–ASC Therapeutics, a privately-held biopharmaceutical company pioneering the development of transformative in-vivo gene replacement, gene editing and allogeneic cell therapies, today announced a

BusinessWire Transformational in-vivo AAV gene therapy for hemophilia A Efficiently biosynthesized and secreted bioengineered factor VIII Potentially leads to lower vector dose, reduced cost and